Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation | Synapse

August 23, 2023Open Access

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Treatment with divarasib resulted in durable clinical responses across KRAS G12C-positive tumors, with mostly low-grade adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT04449874.).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Sacher et al. (Wed,) studied this question.

synapsesocial.com/papers/69dea71e6bae133e7de947b3 https://doi.org/https://doi.org/10.1056/nejmoa2303810

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Adaptive mutability of colorectal cancers in response to targeted therapies2019 · 447 citations
2Largest evaluation of acquired resistance to sotorasib in <i>KRAS</i> p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.2022 · 27 citations
3K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions2013 · 2,511 citations
4Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors2022 · 169 citations
5First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup><i>G12C</i></sup> Solid Tumors (KRYSTAL-1)2022 · 301 citations